Effects of interleukin-1 receptor antagonist in a slow-release hylan vehicle on rat type II collagen arthritis

Pharmaceutical Research

Volumn 15, Issue 10, 1998, Pages 1557-1561

  Bendele, Alison ^a   McAbee, Tracy ^a   Woodward, Melissa ^a   Scherrer, Jon ^a   Collins, Dave ^a   Frazier, Jan ^a   Chlipala, Elizabeth ^a   McCabe, Dorothy ^a  

^a AMGEN INC   (United States)

Author keywords

Hylan; Interleukin I receptor antagonist; Rat; Type II collagen arthritis

Indexed keywords

COLLAGEN TYPE 2; DRUG VEHICLE; EDETIC ACID; HYLAN FLUID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; POLYSORBATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; FEMALE; IMMUNOMODULATION; INTRADERMAL DRUG ADMINISTRATION; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

ANIMALS; ARTHRITIS, RHEUMATOID; COLLAGEN; FEMALE; HYALURONIC ACID; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; RATS; RATS, INBRED LEW; SIALOGLYCOPROTEINS; VEHICLES;

EID: 0031710789     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011903100188     Document Type: Article

References (19)

1. S. P. Eisenberg, R. J. Evans, and W. P. Arend. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 343:341-5 (1990).
2. G. V. Campion, M. E. Lebsack, J. Lookabaugh, G. Gordon, M. Catalano, and The IL-1ra arthritis study group. Dose-range and dose-frequency study of recombinant interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 39:1092-1101 (1996).
3. D. E. Trentham, A. S. Townes, and A. H. Kang. Autoimmunity to type II collagen: an experimental model of arthritis. J. Exp. Med. 146:857-868 (1977).
4. K. Terato, R. Hashida, K. Miyamoto, T. Morimoto, Y. Kata, S. Kobayashi, T. Tajima, S. Otake, H. Homi, and Y. Nagai. Histological, immunological, and biochemical studies on type II collagen arthritis in rats. Biomed. Res. 3:495-523 (1982).
5. T. Maack, V. Johnson, S. T. Kau, J. Figueiredo, and D. Sigulem. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidneys International 16:251-270 (1979).
6. N. E. Larsen and E. A. Balazs. Drug delivery systems using hyaluronan and its derivatives. Adv. Drug Delivery Rev. 7:279-293 (1991).
7. R. Cortivo, P. Brun, A. Rastrelli, and G. Abatangelo. In vitro studies on biocompatibility of hyaluronic acid esters. Biomaterials 2:727-730 (1991).
8. N. E. Larsen, C. T. Pollak, K. Reiner, E. Leshchiner, and E. A. Balazs. Hylan gel biomaterial: dermal and immunologic compatibility. J Biomed. Materials Res. 27:1129-1134 (1993).
9. H. Bothner and D. Wik. Rheology of hyaluronate. Acta Otolaryngol. (Stockholm) Suppl. 442:25-30 (1987).
10. J. A. Hunt, H. N. Joshi, V. J. Stella, and E. M. Topp. Diffusion and drug release in polymer films prepared from ester derivatives of hyaluronic acid. J. Contr. Rel. 12:159-169 (1990).
11. L. Illum, N. F. Farraj, A. N. Fisher, I. Gill, M. Miglietta, and L. M. Bendetti. Hyaluronic acid microspheres as a nasal delivery system for insulin. J. Contr. Rel. 29:133-141 (1994).
12. P. T. Prisell, O. Camber, J. Hiselius, and G. Norstedt. Evaluation of hyaluronan as a vehicle for peptide growth factors. Int. J. Pharm. 85:51-56 (1992).
13. E. Ghezzo, L. M. Benedetti, M. Rochiva, F. Bivano, and L. Callagaro. Hyaluronic acid derivative microspheres as NGF delivery devices: preparation methods and in vitro release characterization. Int. J. Pharm. 87:21-29 (1992).
14. J. Meyer, L. Whitcomb, M. Treuheit, and D. Collins. Sustained in vivo activity of recombinant human granulocyte colony stimulating factor (rHG-CSF) incorporated into hyaluronan. J. Contr. Rel. 35:67-72 (1995).
15. C. A. Dinarello. Biologic basis for interleukin-1 in disease. Blood 87:2095-2147 (1996).
16. W. P. Arend and J. P. Dayer. Inhibition of the production and effects of interleukin-I and tumor necrosis factor-in rheumatoid arthritis. Arthritis Rheum. 38:151-160 (1995).
17. J. A. Eastgate, N. C. Wood, F. S. diGiovine, J. A. Symons, F. M. Grinlinton, and G. W. Duff. Correlation of plasma interleukin-I levels with disease activity in rheumatoid arthritis. Lancet. Sept. 24:706-709 (1988).
18. J. H. Schwab, S. K. Anderle, R. R. Brown, F. G. Dalldorf, and R. C. Thompson. Pro- and anti-inflammatory roles of interleukin-I in recurrence of bacterial cell wall-induced arthritis in rats. Infection Immunity 59:4436-4442 (1991).
19. L. A. B. Joosten, M. M. A. Helsen, F. A. J. van de Loo, and W. B. van den Berg. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. Arthritis Rheum. 39:797-809 (1996).